Symbols / GRCE Stock $2.10 -2.78% Grace Therapeutics, Inc.

Healthcare • Biotechnology • United States • NCM
GRCE (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Mr. Prashant Kohli
Exch · Country NCM · United States
Market Cap 32.50M
Enterprise Value 13.82M
Income -5.98M
Sales —
FCF (ttm) -6.62M
Book/sh 4.19
Cash/sh 1.21
Employees 6
Insider 10d —
IPO Feb 07, 2012
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -3.01
PEG —
P/S —
P/B 0.50
P/C —
EV/EBITDA -1.23
EV/Sales —
Quick Ratio 14.56
Current Ratio 14.96
Debt/Eq —
LT Debt/Eq —
EPS (ttm) -0.31
EPS next Y -0.70
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-02-12
Earnings (prior) 2026-02-12
ROA -10.84%
ROE -10.22%
ROIC —
Gross Margin 0.00%
Oper. Margin 0.00%
Profit Margin 0.00%
Shs Outstand 15.47M
Shs Float 9.77M
Insider Own 27.06%
Instit Own 28.02%
Short Float 14.82%
Short Ratio 2.24
Short Interest 1.95M
52W High 5.18
vs 52W High -59.46%
52W Low 1.79
vs 52W Low 17.32%
Beta 0.69
Impl. Vol. 12.50%
Rel Volume 0.84
Avg Volume 694.76K
Volume 582.17K
Target (mean) $6.00
Tgt Median $6.00
Tgt Low $4.00
Tgt High $8.00
# Analysts 2
Recom Strong_buy
Prev Close $2.16
Price $2.10
Change -2.78%
About

Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray of betamethasone to improve neurological symptoms of Ataxia-Telangiectasia (A-T) and GTX-101, a topical bioadhesive film-forming polymer for the treatment of pain associated with postherpetic neuralgia (PHN). The company was formerly known as Acasti Pharma Inc. and changed its name to Grace Therapeutics, Inc. in October 2024. Grace Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$6.00
Mean price target
2. Current target
$2.10
Latest analyst target
3. DCF / Fair value
$-7.70
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$2.10
Low
$4.00
High
$8.00
Mean
$6.00

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-04-24 main TD Cowen Buy → Buy $8
2025-02-18 reit HC Wainwright & Co. Buy → Buy $12
News
RSS: Latest GRCE news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2025-02-11 Kavuru (Vimal) Director of Issuer — 147,275 $3.40 $499,998
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-03-31 2024-03-31 2023-03-31 2022-03-31
Total Revenue
0.00
0.00
0.00
0.00
Operating Revenue
0.00
0.00
0.00
0.00
Cost Of Revenue
—
—
—
0.00
Reconciled Cost Of Revenue
—
—
—
0.00
Gross Profit
—
—
—
0.00
Operating Expense
16.68
+46.73%
11.37
-37.70%
18.25
+18.95%
15.34
Research And Development
9.51
+103.10%
4.68
-53.04%
9.97
+79.38%
5.56
Selling General And Administration
7.16
+7.78%
6.64
-19.09%
8.21
-16.04%
9.78
Selling And Marketing Expense
—
0.19
+42.65%
0.14
+17.24%
0.12
General And Administrative Expense
7.16
+7.78%
6.64
-17.73%
8.08
-16.44%
9.66
Salaries And Wages
2.54
+34.02%
1.90
-52.64%
4.01
+37.99%
2.91
Other Gand A
4.62
-2.72%
4.75
+16.70%
4.07
-39.84%
6.76
Total Expenses
16.68
+46.73%
11.37
-37.70%
18.25
+18.95%
15.34
Operating Income
-16.68
-46.73%
-11.37
+37.70%
-18.25
-18.95%
-15.34
Total Operating Income As Reported
-16.68
-29.78%
-12.85
+75.36%
-52.16
-234.56%
-15.59
EBITDA
-16.67
-47.19%
-11.33
+37.50%
-18.12
-18.14%
-15.34
Normalized EBITDA
-19.87
-179.98%
-7.10
-144.79%
15.85
+179.28%
-19.99
Reconciled Depreciation
0.01
-36.36%
0.01
-91.13%
0.12
0.00
EBIT
-16.68
-46.73%
-11.37
+37.70%
-18.25
-18.95%
-15.34
Total Unusual Items
3.20
+175.69%
-4.23
+87.55%
-33.97
-830.69%
4.65
Total Unusual Items Excluding Goodwill
3.20
+175.69%
-4.23
+87.55%
-33.97
-830.69%
4.65
Special Income Charges
0.00
+100.00%
-1.49
+95.62%
-33.91
-13517.67%
-0.25
Impairment Of Capital Assets
—
0.00
-100.00%
33.51
0.00
Restructuring And Mergern Acquisition
0.00
-100.00%
1.49
0.00
—
Write Off
—
0.00
-100.00%
0.40
+60.64%
0.25
Net Income
-9.57
+25.56%
-12.85
+69.71%
-42.43
-332.11%
-9.82
Pretax Income
-12.77
+13.06%
-14.69
+71.74%
-51.97
-396.52%
-10.47
Net Non Operating Interest Income Expense
0.71
-21.95%
0.91
+270.33%
0.25
+219.48%
0.08
Net Interest Income
0.71
-21.95%
0.91
+270.33%
0.25
+219.48%
0.08
Interest Income Non Operating
0.71
-21.95%
0.91
+270.33%
0.25
+219.48%
0.08
Interest Income
0.71
-21.95%
0.91
+270.33%
0.25
+219.48%
0.08
Other Income Expense
3.20
+175.69%
-4.23
+87.55%
-33.97
-808.30%
4.80
Other Non Operating Income Expenses
—
—
—
0.15
Gain On Sale Of Security
3.20
+216.65%
-2.74
-4325.81%
-0.06
-101.27%
4.90
Tax Provision
-3.20
-74.62%
-1.83
+80.80%
-9.54
-1372.53%
-0.65
Tax Rate For Calcs
0.00
+100.96%
0.00
-32.08%
0.00
+196.57%
0.00
Tax Effect Of Unusual Items
0.80
+252.11%
-0.53
+91.54%
-6.24
-2267.01%
0.29
Net Income Including Noncontrolling Interests
-9.57
+25.56%
-12.85
+69.71%
-42.43
-332.11%
-9.82
Net Income From Continuing Operation Net Minority Interest
-9.57
+25.56%
-12.85
+69.71%
-42.43
-332.11%
-9.82
Net Income From Continuing And Discontinued Operation
-9.57
+25.56%
-12.85
+69.71%
-42.43
-332.11%
-9.82
Net Income Continuous Operations
-9.57
+25.56%
-12.85
+69.71%
-42.43
-332.11%
-9.82
Normalized Income
-11.97
-30.77%
-9.15
+37.73%
-14.70
-3.64%
-14.18
Net Income Common Stockholders
-9.57
+25.56%
-12.85
+69.71%
-42.43
-332.11%
-9.82
Diluted EPS
-0.79
+41.48%
-1.35
+76.36%
-5.71
-252.47%
-1.62
Basic EPS
-0.79
+41.48%
-1.35
+76.36%
-5.71
-252.47%
-1.62
Basic Average Shares
12.09
+26.85%
9.53
+28.16%
7.44
+21.09%
6.14
Diluted Average Shares
12.09
+26.85%
9.53
+28.16%
7.44
+21.09%
6.14
Diluted NI Availto Com Stockholders
-9.57
+25.56%
-12.85
+69.71%
-42.43
-332.11%
-9.82
Depreciation Amortization Depletion Income Statement
0.01
-82.50%
0.04
-36.51%
0.06
0.00
Depreciation And Amortization In Income Statement
0.01
-82.50%
0.04
-36.51%
0.06
0.00
Depreciation Income Statement
0.01
-82.50%
0.04
-36.51%
0.06
0.00
Total Other Finance Cost
—
—
—
-0.15
Line Item Trend 2025-03-31 2024-03-31 2023-03-31 2022-03-31
Total Assets
71.99
-1.78%
73.30
-7.36%
79.12
-38.48%
128.62
Current Assets
22.71
-5.41%
24.01
-18.03%
29.29
-35.32%
45.28
Cash Cash Equivalents And Short Term Investments
22.13
-3.79%
23.00
-17.52%
27.89
-36.12%
43.66
Cash And Cash Equivalents
22.13
-3.79%
23.00
-17.47%
27.88
-8.12%
30.34
Cash Financial
—
—
27.88
-8.12%
30.34
Other Short Term Investments
—
0.00
-100.00%
0.01
-99.89%
13.32
Receivables
0.13
-82.55%
0.72
-9.98%
0.80
+46.35%
0.55
Other Receivables
0.02
-94.88%
0.39
-5.10%
0.41
+16.71%
0.35
Taxes Receivable
0.11
-66.46%
0.32
-6.51%
0.34
+83.70%
0.18
Accrued Interest Receivable
0.00
-100.00%
0.01
-71.15%
0.05
+372.73%
0.01
Prepaid Assets
0.45
+60.07%
0.28
-52.68%
0.60
-16.94%
0.72
Assets Held For Sale Current
—
—
0.00
-100.00%
0.35
Total Non Current Assets
49.28
-0.02%
49.29
-1.09%
49.83
-40.20%
83.34
Net PPE
0.01
-37.50%
0.02
-95.77%
0.57
+0.35%
0.56
Gross PPE
0.03
-96.40%
0.72
-38.61%
1.18
+16.32%
1.01
Accumulated Depreciation
-0.01
+98.42%
-0.70
-14.61%
-0.61
-36.55%
-0.45
Machinery Furniture Equipment
0.03
-82.78%
0.15
+18.90%
0.13
+14.41%
0.11
Other Properties
—
0.57
-45.57%
1.05
+16.56%
0.90
Goodwill And Other Intangible Assets
49.27
+0.00%
49.27
+0.00%
49.27
-40.48%
82.77
Goodwill
8.14
+0.00%
8.14
+0.00%
8.14
-37.23%
12.96
Other Intangible Assets
41.13
+0.00%
41.13
+0.00%
41.13
-41.09%
69.81
Total Liabilities Net Minority Interest
5.38
-53.42%
11.56
+3.48%
11.17
-45.12%
20.35
Current Liabilities
1.93
+14.61%
1.68
-50.63%
3.41
+4.63%
3.26
Payables And Accrued Expenses
1.93
+14.61%
1.68
-49.52%
3.34
+5.70%
3.16
Payables
1.26
-16.31%
1.51
-36.90%
2.39
-16.43%
2.86
Accounts Payable
0.60
-40.32%
1.01
-18.92%
1.24
-25.98%
1.68
Other Payable
0.66
+31.94%
0.50
-56.36%
1.15
-2.88%
1.18
Current Accrued Expenses
0.67
+279.55%
0.18
-81.40%
0.95
+219.59%
0.30
Current Debt And Capital Lease Obligation
—
—
0.07
-27.88%
0.10
Current Capital Lease Obligation
—
0.00
-100.00%
0.07
-27.88%
0.10
Total Non Current Liabilities Net Minority Interest
3.45
-65.03%
9.87
+27.28%
7.76
-54.61%
17.09
Long Term Debt And Capital Lease Obligation
—
0.00
-100.00%
0.41
+114.66%
0.19
Long Term Capital Lease Obligation
—
0.00
-100.00%
0.41
+114.66%
0.19
Non Current Deferred Liabilities
2.31
-58.07%
5.51
-24.95%
7.35
-56.50%
16.89
Non Current Deferred Taxes Liabilities
2.31
-58.07%
5.51
-24.95%
7.35
-56.50%
16.89
Stockholders Equity
66.61
+7.88%
61.74
-9.14%
67.95
-37.24%
108.27
Common Stock Equity
66.61
+7.88%
61.74
-9.14%
67.95
-37.24%
108.27
Capital Stock
0.00
+0.00%
0.00
-100.00%
258.29
+0.12%
257.99
Common Stock
0.00
+0.00%
0.00
-100.00%
258.29
+0.12%
257.99
Preferred Stock
0.00
0.00
—
—
Share Issued
13.72
+45.95%
9.40
+26.41%
7.44
+0.73%
7.38
Ordinary Shares Number
13.72
+45.95%
9.40
+26.41%
7.44
+0.73%
7.38
Additional Paid In Capital
293.33
+5.18%
278.90
+1897.13%
13.96
+14.90%
12.15
Retained Earnings
-220.69
-4.53%
-211.12
-6.48%
-198.27
-27.23%
-155.84
Gains Losses Not Affecting Retained Earnings
-6.04
+0.00%
-6.04
+0.00%
-6.04
-0.02%
-6.04
Other Equity Adjustments
-6.04
+0.00%
-6.04
+0.00%
-6.04
-0.02%
-6.04
Total Equity Gross Minority Interest
66.61
+7.88%
61.74
-9.14%
67.95
-37.24%
108.27
Total Capitalization
66.61
+7.88%
61.74
-9.14%
67.95
-37.24%
108.27
Working Capital
20.78
-6.92%
22.33
-13.73%
25.88
-38.41%
42.02
Invested Capital
66.61
+7.88%
61.74
-9.14%
67.95
-37.24%
108.27
Total Debt
—
0.00
-100.00%
0.48
+64.41%
0.29
Capital Lease Obligations
—
0.00
-100.00%
0.48
+64.41%
0.29
Net Tangible Assets
17.34
+39.01%
12.48
-33.24%
18.69
-26.70%
25.50
Tangible Book Value
17.34
+39.01%
12.48
-33.24%
18.69
-26.70%
25.50
Derivative Product Liabilities
1.14
-73.82%
4.36
0.00
-100.00%
0.01
Line Item Trend 2025-03-31 2024-03-31 2023-03-31 2022-03-31
Operating Cash Flow
-14.90
-20.85%
-12.33
+22.50%
-15.91
+7.67%
-17.23
Cash Flow From Continuing Operating Activities
-14.90
-20.85%
-12.33
+22.50%
-15.91
+7.67%
-17.23
Net Income From Continuing Operations
-9.57
+25.56%
-12.85
+69.71%
-42.43
-332.11%
-9.82
Depreciation Amortization Depletion
0.01
-36.36%
0.01
-91.13%
0.12
0.00
Depreciation
0.01
-36.36%
0.01
-91.13%
0.12
0.00
Amortization Cash Flow
—
—
—
0.00
Depreciation And Amortization
0.01
-36.36%
0.01
-91.13%
0.12
0.00
Amortization Of Intangibles
—
—
—
0.00
Stock Based Compensation
0.73
-20.04%
0.91
-49.59%
1.81
+35.45%
1.34
Asset Impairment Charge
—
0.00
-100.00%
33.91
+13517.67%
0.25
Deferred Tax
-3.20
-74.62%
-1.83
+80.80%
-9.54
-1372.53%
-0.65
Deferred Income Tax
-3.20
-74.62%
-1.83
+80.80%
-9.54
-1372.53%
-0.65
Operating Gains Losses
-3.22
-218.76%
2.71
+7864.71%
0.03
+100.61%
-5.57
Gain Loss On Investment Securities
-3.22
-217.96%
2.73
+27380.00%
-0.01
+99.81%
-5.20
Net Foreign Currency Exchange Gain Loss
—
0.00
-100.00%
0.01
+101.35%
-0.37
Gain Loss On Sale Of PPE
0.00
+100.00%
-0.06
0.00
—
Change In Working Capital
0.34
+126.72%
-1.28
-807.18%
0.18
+106.50%
-2.79
Change In Receivables
0.60
+645.00%
0.08
+126.49%
-0.30
-1577.78%
-0.02
Change In Prepaid Assets
-0.17
-153.97%
0.32
+337.50%
0.07
+118.95%
-0.38
Change In Payables And Accrued Expense
-0.08
+94.92%
-1.65
-501.95%
0.41
+117.21%
-2.39
Change In Payable
-0.08
+94.92%
-1.65
-501.95%
0.41
+117.21%
-2.39
Change In Other Current Assets
0.00
+100.00%
-0.02
0.00
0.00
Investing Cash Flow
0.00
-100.00%
0.10
-99.21%
13.15
+473.45%
-3.52
Cash Flow From Continuing Investing Activities
0.00
-100.00%
0.10
-99.21%
13.15
+473.45%
-3.52
Net PPE Purchase And Sale
0.00
-100.00%
0.09
+623.53%
-0.02
0.00
Purchase Of PPE
0.00
+100.00%
-0.02
-29.41%
-0.02
0.00
Sale Of PPE
0.00
-100.00%
0.11
0.00
—
Capital Expenditure
—
-0.02
-29.41%
-0.02
—
Net Investment Purchase And Sale
0.00
-100.00%
0.01
-99.89%
13.17
+473.94%
-3.52
Purchase Of Investment
-0.01
+99.77%
-6.55
-30.69%
-5.01
+85.64%
-34.93
Sale Of Investment
0.01
-99.77%
6.57
-63.88%
18.18
-42.10%
31.41
Financing Cash Flow
14.03
+90.68%
7.36
+2320.72%
0.30
0.00
Cash Flow From Continuing Financing Activities
14.03
+90.68%
7.36
+2320.72%
0.30
0.00
Net Common Stock Issuance
15.00
+99.99%
7.50
+2367.11%
0.30
0.00
Proceeds From Stock Option Exercised
0.00
-100.00%
0.02
0.00
0.00
Net Other Financing Charges
-0.97
-496.91%
-0.16
—
—
Changes In Cash
-0.87
+82.09%
-4.87
-98.29%
-2.46
+88.17%
-20.76
Effect Of Exchange Rate Changes
—
0.00
+100.00%
-0.01
-105.23%
0.15
Beginning Cash Position
23.00
-17.47%
27.88
-8.12%
30.34
-40.44%
50.94
End Cash Position
22.13
-3.79%
23.00
-17.47%
27.88
-8.12%
30.34
Free Cash Flow
-14.90
-20.63%
-12.36
+22.44%
-15.93
+7.57%
-17.23
Common Stock Issuance
15.00
+99.99%
7.50
+2367.11%
0.30
0.00
Issuance Of Capital Stock
15.00
+99.99%
7.50
+2367.11%
0.30
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category